Immuno-Oncology | Specialty

Atezolizumab/Bevacizumab Demonstrates Durable Efficacy in Advanced Malignant Peritoneal Mesothelioma

July 15th 2021

The combination of atezolizumab plus bevacizumab elicited encouraging, durable responses in patients with advanced malignant peritoneal mesothelioma, irrespective of tumor mutational burden and PD-L1 expression status.

Frontline Bempegaldesleukin/Nivolumab Continues to Elicit Durable Responses in Metastatic Melanoma

July 14th 2021

The combination of bempegaldesleukin plus nivolumab continued to produce promising antitumor activity with favorable tolerability when used in the frontline treatment of patients with metastatic melanoma, according to findings from a phase 2 cohort of the phase 1/2 PIVOT-2 trial.

Belapectin/Pembrolizumab Shows Early Activity, Tolerability in Metastatic Melanoma & Head and Neck Cancer

July 11th 2021

The combination of belapectin plus pembrolizumab has demonstrated early potential for disease control with acceptable tolerability in patients with metastatic melanoma and head and neck cancer.

Emerging Immune Checkpoint Research Focuses on CD137

July 8th 2021

During the past decade, a growing number of PD-1/PD-L1 inhibitors gained FDA approval to treat a wide range of cancer types. Their stimulatory counterparts also emerged as sought-after anticancer targets but have proved much more challenging to manipulate therapeutically.

TIL Therapy LN-145 Elicits 21.4% ORR in Previously Treated Metastatic NSCLC

July 7th 2021

The tumor-infiltrating lymphocyte therapy LN-145 was found to induce an objective response rate of 21.4% in patients with advanced or metastatic non–small cell lung cancer who had progressed following systemic therapy.

Rigosertib/Nivolumab Combo Shows Early Potential in KRAS-Mutated NSCLC

July 6th 2021

The novel combination comprised of rigosertib and nivolumab showed preliminary evidence of potential anticancer activity in patients with advanced metastatic KRAS-mutated non–small cell lung cancer.

Pembrolizumab/Lenvatinib Regimen Being Tested in Advanced Gastroesophageal Adenocarcinoma

July 1st 2021

Frontline pembrolizumab plus lenvatinib, and chemotherapy is being tested against chemotherapy alone in patients with advanced gastroesophageal adenocarcinoma, as part of the international, 2-part, phase 3 LEAP-015 trial.

The Understanding of Immunotherapy Biomarkers Is Rapidly Evolving in Oncology

June 29th 2021

The landscape of immunotherapy biomarkers is rapidly evolving, and future developments are likely to have an impact on patients and clinicians alike.

Leukocyte Interleukin Plus SOC, Without Chemo, Provides 5-Year OS Benefit of 14.1% in Head and Neck Cancer

June 29th 2021

The immunotherapy Leukocyte interleukin followed by surgery and radiotherapy, without chemotherapy, significantly improved overall survival compared with standard of care alone in the treatment of patients with advanced primary squamous cell carcinoma of the head and neck.

Nivolumab/Ipilimumab Approved in Europe for dMMR or MSI-H Metastatic Colorectal Cancer

June 29th 2021

The European Commission has approved the combination of nivolumab plus ipilimumab for use in adult patients with mismatch repair deficient or microsatellite instability–high metastatic colorectal cancer following previous fluoropyrimidine-based combination chemotherapy.

Pembrolizumab/Chemo Approved in Europe for Select Esophageal Cancer or HER2– GEJ Adenocarcinoma

June 29th 2021

The European Commission has approved pembrolizumab plus platinum- and fluoropyrimidine-based chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus or HER2-negative gastroesophageal junction adenocarcinoma whose tumors have PD-L1 expression.

Galinpepimut-S Plus Nivolumab Shows Promising Preliminary Benefit in Mesothelioma

June 28th 2021

The combination of the targeted cancer vaccine galinpepimut-S plus nivolumab resulted in a median overall survival of 35.4 weeks in patients with macroscopic deposits of malignant pleural mesothelioma who had received treatment for at least 1 month.

EU Panel Recommends Adjuvant Nivolumab for Select Esophageal, GEJ Cancers

June 25th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction cancer who have residual pathologic disease after previous neoadjuvant chemoradiotherapy.

ODAC Postpones Decision on Retifanlimab in Advanced Anal Cancer

June 24th 2021

In a 13 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee chose to hold off on a decision regarding accelerated approval for retifanlimab for the treatment of patients with locally advanced or metastatic squamous carcinoma of the anal canal who have progressed on or are intolerant of platinum-based chemotherapy.

Frontline Domvanalimab-Based Combos Elicit Encouraging ORRs in PD-L1–High NSCLC

June 24th 2021

The anti-TIGIT agent domvanalimab in combination with zimberelimab with or without etrumadenant demonstrated promising objective response rates when given as a first-line treatment in patients with metastatic non–small cell lung cancer who have a PD-L1 expression of 50% or higher.

Frontline Pembrolizumab Plus Chemo With or Without Bevacizumab Improves Survival in Cervical Cancer

June 22nd 2021

Pembrolizumab plus platinum-based chemotherapy with or without bevacizumab significantly improved overall survival and progression-free survival over the same platinum-based chemotherapy regimen with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer—irrespective of PD-L1 status.

Quadruplets, Immune-Based Regimens Slated to Expand the Frontline Myeloma Paradigm

June 18th 2021

Daratumumab-based quadruplet regimens and cutting-edge immune-based therapies are positioned to become potential standard options in frontline multiple myeloma treatment.

Frontline Sintilimab Plus Gemcitabine/Platinum Prolongs PFS in Squamous NSCLC

June 18th 2021

The addition of sintilimab to standard chemotherapy comprised of gemcitabine and platinum significantly improved progression-free survival with acceptable safety in previously untreated patients with advanced or metastatic squamous non–small cell lung cancer.

Adjuvant Nivolumab Improves DFS in High-Risk Muscle-Invasive Urothelial Cancer

June 14th 2021

Adjuvant nivolumab led to a significant improvement in disease-free survival compared with placebo in patients with high-risk muscle-invasive urothelial carcinoma following radical surgery, irrespective of PD-L1 expression level.

Patel Previews Collaborative Research Program With SD-101 in Uveal Melanoma

June 10th 2021

Dr. Patel discusses the significance of the new collaboration between The University of Texas MD Anderson Cancer Center and TriSalus™ Life Sciences.